Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

13.740
+1.84015.46%
Volume:18.61M
Turnover:248.80M
Market Cap:13.63B
PE:-41.77
High:13.950
Open:11.920
Low:11.890
Close:11.900
52wk High:18.750
52wk Low:1.480
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:2.81
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.329
ROE:-12.77%
ROA:-12.32%
PB:6.67
PE(LYR):-41.77
PS:5266.30

Loading ...

ASCLETIS-B (01672): ASC47 Combined with GLP-1R/GIPR Dual Receptor Agonist Peptide ASC31 Demonstrates Superior Weight Loss Effects Compared to ASC47 Plus Tirzepatide Combination in Obese Animal Models

Stock News
·
Aug 18

Ascletis Pharma Inc - Combination of Asc47 and Asc31 Shows Greater Weight Loss

THOMSON REUTERS
·
Aug 18

BRIEF-Ascletis Pharma H1 Net Income RMB -88 Million

Reuters
·
Aug 15

Ascletis Pharma Narrows Loss by 33% in H1

MT Newswires Live
·
Aug 15

ASCLETIS-B (01672) Reports Interim Results with Shareholder Loss of RMB 87.951 Million, Narrowing 32.5% Year-on-Year

Stock News
·
Aug 15

HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%

Tiger Newspress
·
Aug 15

BUZZ-Ascletis hits record high on weight loss drug's potential in early trial

Reuters
·
Aug 13

Ascletis' ASC47-Tirzepatide Combo Delivers 87% Greater Weight Loss in Preclinical Study

MT Newswires Live
·
Aug 13

BRIEF-Ascletis Pharma Says ASC47 Showed Greater Efficacy With Tirzepatide

Reuters
·
Aug 13

Ascletis Announces Asc47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy With Tirzepatide Than Semaglutide in a Preclinical Model

THOMSON REUTERS
·
Aug 13

Ascletis Pharma Inc - Announces Asc47 Shows Greater Efficacy With Tirzepatide

THOMSON REUTERS
·
Aug 13

Ascletis Pharma Completes Enrollment in Obesity Drug Study in the US

MT Newswires Live
·
Aug 05

HK Movers | Biotech Stocks Extend Rally. Junshi Bio up over 24%; Genor up 23%; Ascletis up 15%; Ascentage up 13%; Dualitybio up 12%

Tiger Newspress
·
Aug 05

Ascletis Announces First Participants With Obesity or Overweight Dosed in Its U.S. 12-Week Phase Iia Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule Glp-1R Agonist Asc30

THOMSON REUTERS
·
Jul 28

Ascletis Pharma Inc. Announces Initiation of U.S. Phase IIA Study for Once-Monthly Subcutaneous GLP-1R Agonist ASC30 for Obesity Treatment

Reuters
·
Jul 28

HK Movers | HK's Biotech Shares Soar. Fudan-zhangjiang Soars 22%; Akeso up 11%; CStone Pharma up 9%

Tiger Newspress
·
Jul 17

Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Reuters
·
Jul 15

HK Movers | Pharma Stocks Shine. Luye Pharma up 8%; Hua Medicine, Hengrui Pharma up 7%; Sino Biopharm, Fudan Zhangjiang up over 3%

Tiger Newspress
·
Jul 09

HK Movers|Biotech Stocks Gained. RemeGen, Junshi Bio And TigerMed Up 3%; Laekna And JW Therap Up 1%

Tiger Newspress
·
Jul 08

HK Movers|HK Innovative Drug Concept Stocks Rose. Biostar Up 15%; Akeso Up 11%; SKB Bio And Innovent Bio Up More Than 7%

Tiger Newspress
·
Jul 03